April 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved mometasone furoate inhalation powder for the maintenance treatment of asthma as prophylactic therapy in patients aged 12 ...
Merck & Co says that it has won US Food and Drug Administration clearance for a new version of its osteoporosis treatment, Fosamax Plus D (alendronate sodium/cholecalciferol) – a once-weekly tablet ...
CHICAGO (AP) _ Hormone supplements plus a bone-building drug work better at increasing bone density than either treatment alone in older women, a study suggests. The study involved 373 women ages 65 ...
Merck & Company's Fosamax Plus D (alendronate sodium/cholecalciferol), a single once-weekly tablet containing 70 mg Fosamax (alendronate sodium) and 2800 IU vitamin D3, representing seven days worth ...
Merck Sharp & Dohme New Zealand (MSDNZ) has gained registration for its osteoporosis medication FOSAMAX PLUS™ 5600 IU. MSDNZ Managing Director, Alister Brown, says "This will be welcome news for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results